In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.